An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases

By M. Ghany, D. Nelson, D. Strader, David L. Thomas, L. Seeff. Hepatology, 2011

1,165 citations recorded by the source corpus.

The standard of care (SOC) therapy for patients with chronic hepatitis C virus (HCV) infection has been the use of both peginterferon (PegIFN) and ribavirin (RBV). These drugs are administered for either 48 weeks (HCV genotypes 1, 4, 5, and 6) or for 24 weeks (HCV genotypes 2 and 3), inducing sustained virologic response (SVR) rates of 40%-50% in those with genotype 1 and of 80% or more in those with genotypes 2 and 3 infections.5-7 Once achieved, an SVR is associated with long-term clearance of HCV infection, which is regarded as a virologic “cure,” as well as with improved morbidity and mortality.8-10 Two major advances have occurred since the last update of treatment guidelines for chronic hepatitis C (CHC) that have changed the optimal treatment regimen of genotype 1 chronic HCV infection: the development of direct-acting antiviral (DAA) agents11-17 and the identification of several single-nucleotide polymorphisms associated with spontaneous and treatment-induced clearance of HCV infection.18,19 Although PegIFN and RBV remain vital components of therapy, the emergence of DAAs has led to a substantial improvement in SVR rates and the option of abbreviated therapy in many patients with genotype 1 chronic HCV infection. A revision of the prior treatment guidelines is therefore necessary, but is based on data that are presently limited. Accordingly, there may be need to reconsider some of the recommendations as additional data become available. These guidelines review what treatment for genotype 1 chronic HCV infection is now regarded as optimal, but they do not address the issue of prioritization of patient selection for treatment or of treatment of special patient populations.

Subfields: Epidemiology, Hepatology

View Paper: https://www.semanticscholar.org/paper/77cafcee825eee943ddb18ee411e7ae1a1c6a631

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. Sudhakar Kundapur Venkatesh
2. M. Yin
3. R. Ehman

Citations in the corpus

• Magnetic Resonance Elastography of Liver: Technique, Analysis and Clinical Applications (2013, background): “Moreover, practice guidelines for treatment of chronic hepatitis C infection with recently approved protease inhibitor drugs require an assessment of fibrosis staging to determine the recommended duration of therapy with these effective but very expensive drugs (9,10).”